Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970966 | 1.00 | CA1 (0.48) | CA1CA2CA7CA9LMNA | |
| SCHEMBL10587296 | 1.00 | CA1 (0.48) | CA1CA2CA7CA9LMNA | |
| SCHEMBL8373146 | 1.00 | CA1 (0.48) | CA1CA2CA7CA9LMNA | |
| SCHEMBL2863103 | 0.96 | CA1 (0.48) | CA1CA2CA7CA9LMNA | |
| SCHEMBL657952 | 0.96 | CA1 (0.48) | CA1CA2CA7CA9LMNA | |
| SCHEMBL11059349 | 0.96 | CA1 (0.48) | CA1CA2CA7CA9LMNA | |
| Ethylene Glycol SCHEMBL28198773 | 0.92 | CA1 (0.46) | CA1CA2CA7CA9LMNA | |
| Xylitol SCHEMBL3293322 | 0.89 | LMNA (0.46) | CA1CA2CA7CA9LMNA | |
| Adonitol SCHEMBL3970962 | 0.89 | LMNA (0.46) | CA1CA2CA7CA9LMNA | |
| Phosphoric Acid SCHEMBL2859329 | 0.87 | CA1 (0.42) | CA1CA2CA7CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108951169-B | Preparation method of natural alcohol ether modified organosilicon hydrophilic softening agent | 杭州美高华颐化工有限公司 | 2021-02-09 | — | — | CN | claimed |
| US-8138248-B2 | Method to improve cold flow resistance of polymers | BRIDGESTONE CORPORATION (JP) | 2012-03-20 | — | — | US | claimed |
| CN-101925349-A | Orally disintegrating tablet composition of temazepam | EURAND INC | 2010-12-22 | — | — | CN | claimed |
| US-20100004361-A1 | METHOD TO IMPROVE COLD FLOW RESISTANCE OF POLYMERS | BRIDGESTONE CORPORATION (JP) | 2010-01-07 | — | — | US | claimed |
| WO-2009086046-A1 | ORALLY DISINTEGRATING TABLET COMPOSITIONS OF TEMAZEPAM | EURAND, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| US-20090169620-A1 | ORALLY DISINTEGRATING TABLET COMPOSITIONS OF TEMAZEPAM | ADARE DEVELOPMENT I, L.P. | 2009-07-02 | — | — | US | claimed |
| CN-111971025-B | Cross-linking compositions, personal care compositions comprising the same and methods of forming | 美国陶氏有机硅公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-2492301-B1 | NOVEL CO-MODIFIED ORGANOPOLYSILOXANE | DOW TORAY CO LTD (JP) | 2023-03-29 | — | — | EP | disclosed |
| EP-3787594-B1 | CROSS-LINKED COMPOSITION, PERSONAL CARE COMPOSITION INCLUDING THE SAME, AND METHODS OF FORMATION | DOW SILICONES CORP (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-109745244-B | Whitening essence | 西安博鸿生物技术有限公司 | 2021-12-24 | — | — | CN | disclosed |
| CN-107690329-B | Pituitous silicone emulsions | 美国陶氏有机硅公司 | 2021-10-08 | — | — | CN | disclosed |
| US-20210236409-A1 | CROSS-LINKED COMPOSITION, PERSONAL CARE COMPOSITION INCLUDING THE SAME, AND METHODS OF FORMATION | DOW SILICONES CORP (US) | 2021-08-05 | — | — | US | disclosed |
| EP-3448974-B1 | DETERGENT COMPOSITION COMPRISING A CARBINOL FUNCTIONAL TRISILOXANE | DOW SILICONES CORP (US) | 2021-07-07 | — | — | EP | disclosed |
| US-7157510-B2 | Method of nucleating a polyolefin composition with acetal-based compounds | MILLIKEN & COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| WO-2006044187-A1 | A METHOD FOR PREPARING ACETAL-CONTAINING COMPOSITIONS AND RELATED COMPOSITIONS AND ARTICLES | MILLIKEN & COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079720-A1 | Method for preparing acetal-containing compositions | MILLIKEN & COMPANY | 2006-04-13 | — | — | US | disclosed |
| WO-2005111134-A2 | METHOD OF NUCLEATING A POLYOLEFIN COMPOSITION WITH ACETAL-BASED COMPOUNDS | MILLIKEN & COMPANY (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005108479-A2 | ACETAL-BASED COMPOSITIONS | MILLIKEN & COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050239928-A1 | Acetal-based compositions | MILLIKEN & COMPANY | 2005-10-27 | — | — | US | disclosed |
| US-20050239926-A1 | Method of nucleating a polyolefin composition with acetal-based compounds | MILLIKEN & COMPANY | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236409-A1 | CROSS-LINKED COMPOSITION, PERSONAL CARE COMPOSITION INCLUDING THE SAME, AND METHODS OF FORMATION | PLOD2, PLOD1, PLOD3 | CA1 202/4885CA2 425/4885CA7 20/4885 |
| US-20090169620-A1 | ORALLY DISINTEGRATING TABLET COMPOSITIONS OF TEMAZEPAM | SORD, GABRQ, KCNT1 | CA1 1353/4885CA2 2476/4885CA7 1929/4885 |
| US-20050239928-A1 | Acetal-based compositions | PCNA, RAD51, AR | CA1 1596/4885CA2 2980/4885CA7 961/4885 |
| US-20060079720-A1 | Method for preparing acetal-containing compositions | ADH1C, ME1, ADH5 | CA1 27/4885CA2 276/4885CA7 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.